Myriad Genetics (MYGN) Q2 Revenue Up 6%

Myriad Genetics (MYGN) reported Q2 2025 revenue of $213.1 million and adjusted EPS of $0.05, both exceeding estimates, driven by strong pricing and product mix. However, a significant $316.7 million non-cash impairment charge led to a GAAP net loss, and the company continued to report negative adjusted free cash flow of $(17.1) million. Despite these challenges, including volume declines in some segments and payer pressure, MYGN raised its FY2025 revenue and gross margin guidance, bolstered by a new $200 million credit facility, indicating a complex outlook balancing strategic progress in oncology with ongoing operational and financial headwinds.

Analysis

Myriad Genetics (MYGN) presented a mixed financial picture in its Q2 2025 results, characterized by a top-line beat offset by significant underlying weaknesses. Revenue of $213.1 million surpassed consensus estimates by 5.6%, and adjusted EPS of $0.05 exceeded expectations, driven primarily by favorable pricing and an improved product mix rather than volume growth. However, this was overshadowed by a substantial $316.7 million non-cash impairment charge, concentrated in the Women’s Health and Pharmacogenomics segments, which resulted in a large GAAP net loss and signals concerns about the long-term profitability of these units. The company's cash position remains a key concern, with operating cash flow negative at $13.6 million and adjusted free cash flow negative at $(17.1) million, contributing to a 27.3% decline in cash and equivalents since the end of FY2024. While a new $200 million credit facility shores up near-term liquidity, it does not solve the fundamental cash burn. Segment performance was divergent: the Oncology business showed strength with hereditary cancer test volumes up 9% year-over-year, but Women's Health prenatal test volumes fell 8% due to operational issues, and Pharmacogenomics revenue dropped 12% due to a critical loss of coverage from UnitedHealthcare, highlighting significant payer risk. Despite these headwinds, management raised full-year revenue guidance to $818-$828 million and improved gross margin projections, suggesting confidence in pricing power and its core oncology franchise.

Key Decisions for Investors

• Investors should weigh the positive raised revenue guidance and improving gross margins against the significant $316.7 million impairment charge and persistent negative free cash flow, which signal ongoing operational and financial risks.
• Monitor volume trends closely, particularly in the Women's Health segment to validate management's claim of a one-time system issue, and in Pharmacogenomics to gauge the full impact of the UnitedHealthcare coverage loss.
• Given the negative free cash flow of $(17.1) million, the company's cash utilization rate is a critical metric to watch, as the new $200 million credit facility provides a temporary liquidity bridge, not a long-term solution to cash burn.
• Focus on future growth catalysts, including progress updates on the planned 2026 launches of the molecular residual disease (MRD) and AI-enabled Prolaris tests, as these are key to the long-term investment thesis.